528 material Form 8-K filings that 462 companies we cover made with the SEC in January 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
PTC Therapeutics reported preliminary, unaudited 2024 total revenue of approximately $814 million, which the company said exceeded its guidance, and gave 2025 total revenue guidance of $600 million to $800 million. The 2025 range sits below the 2024 preliminary figure, and the 2024 numbers remain subject to the year-end audit.
Unaudited 2024 total net revenue of approximately $814 million; net product revenue approximately $601 million
Translarna approximately $340 million and Emflaza approximately $207 million in unaudited 2024 net product revenue; Evrysdi royalty revenue approximately $211 million
2025 guidance: total revenue $600 million to $800 million; GAAP R&D and SG&A expense $805 million to $835 million
Results will be presented at the J.P. Morgan Healthcare Conference on January 13, 2025, after which the company enters a quiet period
Ichor Holdings said preliminary fourth quarter 2024 revenue of approximately $233 million was at the high end of its guidance, but expects gross margin and earnings per share to fall below the low end of prior guidance ranges. The company cited higher labor costs, higher-than-anticipated inventory charges and unfavorable product mix, and it now expects first quarter 2025 revenue of $235 million to $250 million and 2025 revenue above current expectations. The results are preliminary, unaudited and subject to completion of audit procedures, and the 10-K for fiscal 2024 has not been filed.
Q4 2024 revenue of approximately $233 million, at the high end of guidance and up over 10% sequentially from Q3 2024
Q4 2024 gross margin of 11% to 12% on a GAAP basis and about 12% non-GAAP; EPS below prior guidance ranges
Q1 2025 revenue outlook of $235 million to $250 million, with gross margin returning to 13% to 15%
Full Q4 and fiscal 2024 results and conference call on February 4, 2025, at 1:30 p.m. PT
On January 8, 2025, SouthState Bank agreed to sell about 170 branch properties in Alabama, Florida, Georgia, North Carolina, South Carolina and Virginia to entities affiliated with Blue Owl Real Estate Capital for about $475 million in cash, and to lease them back under 15-year triple net leases. The company expects a pre-tax gain of about $225 million, but also about $40 million in first-year GAAP rent expense, so the deal trades a one-time gain for ongoing occupancy costs, and the final numbers could change during due diligence.
Sale of about 170 branches to Blue Owl affiliates for about $475 million cash, expected to close in the first quarter of 2025, subject to Blue Owl's due diligence.
Expected pre-tax gain of about $225 million after transaction-related expenses.
First-year rent of about $36 million pretax; GAAP rent expense of about $40 million, partly offset by about $8 million less depreciation.
Lease terms: 15-year initial term, three 5-year renewal options, 2% annual rent escalation; the bank will not close any branches or exit any markets.
Moderna disclosed preliminary, unaudited 2024 product sales of $3.0-3.1 billion and year-end cash of about $9.5 billion, ahead of its January 13, 2025 J.P. Morgan presentation. It also set a 2025 revenue range of $1.5-2.5 billion, mostly in the second half, and projected 2025 cash cost reductions of $1.0 billion and year-end 2025 cash of about $6.0 billion. The 2024 figures remain subject to the ongoing audit, and the filing gives no prior-year comparison for the new 2025 range.
Unaudited 2024 product sales of $3.0-3.1 billion, including $1.7 billion in the U.S.
Year-end 2024 cash, cash equivalents and investments of about $9.5 billion (unaudited).
2025 revenue projected at $1.5-2.5 billion, mostly in the second half; 2025 cash cost reductions of $1.0 billion, with a further $0.5 billion planned for 2026.
Expected year-end 2025 cash and investments of about $6.0 billion; full results due February 14, 2025.
Regeneron released preliminary, unaudited fourth-quarter and full-year 2024 figures at the J.P. Morgan Healthcare Conference, showing aggregate U.S. EYLEA net product sales of $6 billion for the year, up 1%. The company also expects a fourth-quarter acquired in-process R&D charge of approximately $14 million pre-tax, which it says will reduce GAAP and non-GAAP net income per diluted share by about $0.11, and notes that results have not been finalized.
EYLEA HD and EYLEA aggregate U.S. net product sales were $6 billion for 2024, up 1%, and $1.5 billion in the fourth quarter of 2024 (preliminary, unaudited).
Expected fourth-quarter 2024 acquired IPR&D charge of approximately $14 million pre-tax, primarily related to asset acquisitions.
The charge is expected to lower GAAP and non-GAAP net income per diluted share for Q4 2024 by approximately $0.11.
Libtayo exceeded $1 billion in 2024 annual net sales, according to the press release.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.